.png)
Oral Anti-Diabetic Drug Market by Type - Global Industry Analysis & Forecast to 2027
Published On : February 2021 Pages : 155 Category: Pharma & Healthcare Report Code : HC0215827
SEGMENTS & REGIONS:
- Regions: North America, Europe, Asia- Pacific, Latin America, Middle East & Africa
Oral Anti-Diabetic Drug Market By Type (Sulfonylureas, Biguanides, Alpha-Glucosidase Inhibitors, Megalitinides And Others) - Global Industry Analysis & Forecast to 2027
Industry Outlook and Trend Analysis
The Oral Anti-Diabetic Drug Market has encountered significant development over the recent years and is anticipated to grow tremendously over the forecast period.Oral Anti-Diabetic Drug may be classified according to their mechanism of action as insulinotropic or non-insulinotropic. They are available as monotherapy or combination therapies, with the latter involving two antidiabetic drugs and/or insulin.
Drivers and Restraints
Top-down and bottom-up approaches are used to validate the global Oral Anti-Diabetic Drug Marketand estimate the market size for company, regions segments, type segments and applications (end users). In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub segments listed in this report. Extensive qualitative and further quantitative analysis is also done from all the numbers arrived at in the complete market engineering process to list key information throughout the report.
Regional Insights
The data for 2021 is an estimate, based on the history data and the integrated view of industry experts, manufacturers, distributors and end users etc.
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Southeast Asia
- Rest of Asia-Pacific
- SouthAmerica
- Brazil
- Argentina
- Columbia
- Rest of South America
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Nigeria
- South Africa
- Turkey
- Rest of MEA
Competitive Analysis
The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and share of the overall industry.
- Abbott
- AstraZeneca
- Biocon
- Eli Lilly and Company
- Merck & Co., Inc.
- Novartis AG
- Novo Nordisk A/S
- Pfizer Inc.
- Sanofi
- Sun Pharmaceutical Industries Ltd
Some of the key questions answered by the report are:
- What was the market size in 2017 and forecast from 2021 to 2027?
- What will be the industry market growth from 2017 to 2027?
- What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
- What are the major segments leading the market growth and why?
- Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?
Market Classification
· Oral Anti-Diabetic Drug Market , ByType, Estimates and Forecast, 2017-2027 ($Million)
o Sulfonylureas
o Biguanides
o Alpha-Glucosidase Inhibitors
o Megalitinides
o Others
· Oral Anti-Diabetic Drug Market , By Key Players, Estimates and Forecast, 2017-2027 ($Million)
o Abbott
o AstraZeneca
o Biocon
o Eli Lilly and Company
o Merck & Co., Inc.
o Novartis AG
o Novo Nordisk A/S
o Pfizer Inc.
o Sanofi
o Sun Pharmaceutical Industries Ltd
· Oral Anti-Diabetic Drug Market , By Region, Estimates and Forecast, 2017-2027 ($Million)
o North America
§ North America Oral Anti-Diabetic Drug Market , By Country
o U.S. Oral Anti-Diabetic Drug Market
o Canada Oral Anti-Diabetic Drug Market
o Mexico Oral Anti-Diabetic Drug Market
o Europe
§ Europe Oral Anti-Diabetic Drug Market , By Country
o UK Oral Anti-Diabetic Drug Market
o Germany Oral Anti-Diabetic Drug Market
o France Oral Anti-Diabetic Drug Market
o Russia Oral Anti-Diabetic Drug Market
o Italy Oral Anti-Diabetic Drug Market
o Rest of Europe Oral Anti-Diabetic Drug Market
o Asia-Pacific
§ Asia-Pacific Oral Anti-Diabetic Drug Market , By Country
o China Oral Anti-Diabetic Drug Market
o Japan Oral Anti-Diabetic Drug Market
o South Korea Oral Anti-Diabetic Drug Market
o India Oral Anti-Diabetic Drug Market
o Southeast Asia Oral Anti-Diabetic Drug Market
o Rest of Asia-Pacific Oral Anti-Diabetic Drug Market
o South America
§ South America Oral Anti-Diabetic Drug Market
o Brazil Oral Anti-Diabetic Drug Market
o Argentina Oral Anti-Diabetic Drug Market
o Columbia Oral Anti-Diabetic Drug Market
o Rest of South America Oral Anti-Diabetic Drug Market
o Middle East and Africa
§ Middle East and Africa Oral Anti-Diabetic Drug Market
o Saudi Arabia Oral Anti-Diabetic Drug Market
o UAE Oral Anti-Diabetic Drug Market
o Egypt Oral Anti-Diabetic Drug Market
o Nigeria Oral Anti-Diabetic Drug Market
o South Africa Oral Anti-Diabetic Drug Market
o TurkeyOral Anti-Diabetic Drug Market
o Rest of MEA Oral Anti-Diabetic Drug Market
1. Introduction
1.1. Report Description
2. Executive Summary
2.1. Key Highlights
3. Market Overview
3.1. Introduction
3.1.1. Market Definition
3.1.2. Market Segmentation
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
4. Market Analysis by Regions
4.1. North America (United States, Canada and Mexico)
4.1.1. United States Market Status and Outlook (2017-2027)
4.1.2. Canada Market Status and Outlook (2017-2027)
4.1.3. Mexico Market Status and Outlook (2017-2027)
4.2. Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
4.2.1. Germany Market Status and Outlook (2017-2027)
4.2.2. France Market Status and Outlook (2017-2027)
4.2.3. UK Market Status and Outlook (2017-2027)
4.2.4. Russia Market Status and Outlook (2017-2027)
4.2.5. Italy Market Status and Outlook (2017-2027)
4.2.6. Rest of Europe Market Status and Outlook (2017-2027)
4.3. Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)
4.3.1. China Market Status and Outlook (2017-2027)
4.3.2. Japan Market Status and Outlook (2017-2027)
4.3.3. Korea Market Status and Outlook (2017-2027)
4.3.4. India Market Status and Outlook (2017-2027)
4.3.5. Southeast Asia Market Status and Outlook (2017-2027)
4.3.6. Rest of Asia-Pacific Market Status and Outlook (2017-2027)
4.4. South America (Brazil, Argentina, Columbia and Rest of South America)
4.4.1. Brazil Market Status and Outlook (2017-2027)
4.4.2. Argentina Market Status and Outlook (2017-2027)
4.4.3. Columbia Market Status and Outlook (2017-2027)
4.4.4. Rest of South America Market Status and Outlook (2017-2027)
4.5. Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)
4.5.1. Saudi Arabia Market Status and Outlook (2017-2027)
4.5.2. United Arab Emirates Market Status and Outlook (2017-2027)
4.5.3. Egypt Market Status and Outlook (2017-2027)
4.5.4. Nigeria Market Status and Outlook (2017-2027)
4.5.5. South Africa Market Status and Outlook (2017-2027)
4.5.6. Turkey Market Status and Outlook (2017-2027)
4.5.7. Rest of Middle East and Africa Market Status and Outlook (2017-2027)
5. Oral Anti-Diabetic Market, By Type
5.1. Introduction
5.2. Global Oral Anti-Diabetic Revenue and Market Share by Type (2017-2021)
5.2.1. Global Oral Anti-Diabetic Revenue and Revenue Share by Type (2017-2021)
5.3. Sulfonylureas
5.3.1. Global Sulfonylureas Revenue and Growth Rate (2017-2021)
5.4. Biguanides
5.4.1. Global Biguanides Revenue and Growth Rate (2017-2021)
5.5. Alpha-Glucosidase Inhibitors
5.5.1. Global Alpha-Glucosidase Inhibitors Revenue and Growth Rate (2017-2021)
5.6. Megalitinides
5.6.1. Global Megalitinides Revenue and Growth Rate (2017-2021)
5.7. Others
5.7.1. Global Others Revenue and Growth Rate (2017-2021)
6. Oral Anti-Diabetic Market, By Region
6.1. Introduction
6.2. Global Oral Anti-Diabetic Revenue and Market Share by Regions
6.2.1. Global Oral Anti-Diabetic Revenue by Regions (2017-2021)
6.3. North America Oral Anti-Diabetic by Countries
6.3.1. North America Oral Anti-Diabetic Revenue and Growth Rate (2017-2021)
6.3.2. North America Oral Anti-Diabetic Revenue (Million USD) by Countries (2017-2021)
6.3.3. United States
6.3.3.1. United States Oral Anti-Diabetic Revenue (Millions USD) and Growth Rate (2017-2021)
6.3.4. Canada
6.3.4.1. Canada Oral Anti-Diabetic Revenue (Millions USD) and Growth Rate (2017-2021)
6.3.5. Mexico
6.3.5.1. Mexico Oral Anti-Diabetic Revenue (Millions USD) and Growth Rate (2017-2021)
6.4. Europe Oral Anti-Diabetic by Countries
6.4.1. Europe Oral Anti-Diabetic Revenue and Growth Rate (2017-2021)
6.4.2. Europe Oral Anti-Diabetic Revenue (Million USD) by Countries (2017-2021)
6.4.3. Germany
6.4.3.1. Germany Oral Anti-Diabetic Revenue (Millions USD) and Growth Rate (2017-2021)
6.4.4. France
6.4.4.1. France Oral Anti-Diabetic Revenue (Millions USD) and Growth Rate (2017-2021)
6.4.5. UK
6.4.5.1. UK Oral Anti-Diabetic Revenue (Millions USD) and Growth Rate (2017-2021)
6.4.6. Russia
6.4.6.1. Russia Oral Anti-Diabetic Revenue (Millions USD) and Growth Rate (2017-2021)
6.4.7. Italy
6.4.7.1. Italy Oral Anti-Diabetic Revenue (Millions USD) and Growth Rate (2017-2021)
6.4.8. Rest of Europe
6.4.8.1. Rest of Europe Oral Anti-Diabetic Revenue (Millions USD) and Growth Rate (2017-2021)
6.5. Asia-Pacific Oral Anti-Diabetic by Countries
6.5.1. Asia-Pacific Oral Anti-Diabetic Revenue and Growth Rate (2017-2021)
6.5.2. Asia-Pacific Oral Anti-Diabetic Revenue (Million USD) by Countries (2017-2021)
6.5.3. China
6.5.3.1. China Oral Anti-Diabetic Revenue (Millions USD) and Growth Rate (2017-2021)
6.5.4. Japan
6.5.4.1. Japan Oral Anti-Diabetic Revenue (Millions USD) and Growth Rate (2017-2021)
6.5.5. Korea
6.5.5.1. Korea Oral Anti-Diabetic Revenue (Millions USD) and Growth Rate (2017-2021)
6.5.6. India
6.5.6.1. India Oral Anti-Diabetic Revenue (Millions USD) and Growth Rate (2017-2021)
6.5.7. Southeast Asia
6.5.7.1. Southeast Asia Oral Anti-Diabetic Revenue (Millions USD) and Growth Rate (2017-2021)
6.5.8. Rest of Asia-Pacific
6.5.8.1. Rest of Asia-Pacific Oral Anti-Diabetic Revenue (Millions USD) and Growth Rate (2017-2021)
6.6. South America Oral Anti-Diabetic by Countries
6.6.1. South America Oral Anti-Diabetic Revenue and Growth Rate (2017-2021)
6.6.2. South America Oral Anti-Diabetic Revenue (Million USD) by Countries (2017-2021)
6.6.3. Brazil
6.6.3.1. Brazil Oral Anti-Diabetic Revenue (Millions USD) and Growth Rate (2017-2021)
6.6.4. Argentina
6.6.4.1. Argentina Oral Anti-Diabetic Revenue (Millions USD) and Growth Rate (2017-2021)
6.6.5. Columbia
6.6.5.1. Columbia Oral Anti-Diabetic Revenue (Millions USD) and Growth Rate (2017-2021)
6.6.6. Rest of South America
6.6.6.1. Rest of South America Oral Anti-Diabetic Revenue (Millions USD) and Growth Rate (2017-2021)
6.7. Middle East and Africa Oral Anti-Diabetic by Countries
6.7.1. Middle East and Africa Oral Anti-Diabetic Revenue and Growth Rate (2017-2021)
6.7.2. Middle East and Africa Oral Anti-Diabetic Revenue (Million USD) by Countries (2017-2021)
6.7.3. Saudi Arabia
6.7.3.1. Saudi Arabia Oral Anti-Diabetic Revenue (Millions USD) and Growth Rate (2017-2021)
6.7.4. United Arab Emirates
6.7.4.1. United Arab Emirates Oral Anti-Diabetic Revenue (Millions USD) and Growth Rate (2017-2021)
6.7.5. Egypt
6.7.5.1. Egypt Oral Anti-Diabetic Revenue (Millions USD) and Growth Rate (2017-2021)
6.7.6. Nigeria
6.7.6.1. Nigeria Oral Anti-Diabetic Revenue (Millions USD) and Growth Rate (2017-2021)
6.7.7. South Africa
6.7.7.1. South Africa Oral Anti-Diabetic Revenue (Millions USD) and Growth Rate (2017-2021)
6.7.8. Turkey
6.7.8.1. Turkey Oral Anti-Diabetic Revenue (Millions USD) and Growth Rate (2017-2021)
6.7.9. Rest of Middle East and Africa
6.7.9.1. Rest of Middle East and Africa Oral Anti-Diabetic Revenue (Millions USD) and Growth Rate (2017-2021)
7. Company Profiles
7.1. Abbott
7.1.1. Business Overview
7.1.2. Service Portfolio
7.1.3. Strategic Developments
7.1.4. Financial Overview
7.2. AstraZeneca
7.2.1. Business Overview
7.2.2. Service Portfolio
7.2.3. Strategic Developments
7.2.4. Financial Overview
7.3. Biocon
7.3.1. Business Overview
7.3.2. Service Portfolio
7.3.3. Strategic Developments
7.3.4. Financial Overview
7.4. Eli Lilly and Company
7.4.1. Business Overview
7.4.2. Service Portfolio
7.4.3. Strategic Developments
7.4.4. Financial Overview
7.5. Merck & Co., Inc.
7.5.1. Business Overview
7.5.2. Service Portfolio
7.5.3. Strategic Developments
7.5.4. Financial Overview
7.6. Novartis AG
7.6.1. Business Overview
7.6.2. Service Portfolio
7.6.3. Strategic Developments
7.6.4. Financial Overview
7.7. Novo Nordisk A/S
7.7.1. Business Overview
7.7.2. Service Portfolio
7.7.3. Strategic Developments
7.7.4. Financial Overview
7.8. Pfizer Inc.
7.8.1. Business Overview
7.8.2. Service Portfolio
7.8.3. Strategic Developments
7.8.4. Financial Overview
7.9. Sanofi
7.9.1. Business Overview
7.9.2. Service Portfolio
7.9.3. Strategic Developments
7.9.4. Financial Overview
7.10. Sun Pharmaceutical Industries Ltd
7.10.1. Business Overview
7.10.2. Service Portfolio
7.10.3. Strategic Developments
7.10.4. Financial Overview
8. Oral Anti-Diabetic Market Forecast (2022-2027)
8.1. Global Oral Anti-Diabetic Revenue (Millions USD) and Growth Rate (2022-2027)
8.2. Oral Anti-Diabetic Market Forecast by Regions (2022-2027)
8.2.1. North America Oral Anti-Diabetic Market Forecast (2022-2027)
8.2.1.1. United States Oral Anti-Diabetic Market Forecast (2022-2027)
8.2.1.2. Canada Oral Anti-Diabetic Market Forecast (2022-2027)
8.2.1.3. Mexico Oral Anti-Diabetic Market Forecast (2022-2027)
8.2.2. Europe Oral Anti-Diabetic Market Forecast (2022-2027)
8.2.2.1. Germany Oral Anti-Diabetic Market Forecast (2022-2027)
8.2.2.2. France Oral Anti-Diabetic Market Forecast (2022-2027)
8.2.2.3. UK Oral Anti-Diabetic Market Forecast (2022-2027)
8.2.2.4. Russia Oral Anti-Diabetic Market Forecast (2022-2027)
8.2.2.5. Italy Oral Anti-Diabetic Market Forecast (2022-2027)
8.2.2.6. Rest of Europe Oral Anti-Diabetic Market Forecast (2022-2027)
8.2.3. Asia-Pacific Oral Anti-Diabetic Market Forecast (2022-2027)
8.2.3.1. China Oral Anti-Diabetic Market Forecast (2022-2027)
8.2.3.2. Japan Oral Anti-Diabetic Market Forecast (2022-2027)
8.2.3.3. Korea Oral Anti-Diabetic Market Forecast (2022-2027)
8.2.3.4. India Oral Anti-Diabetic Market Forecast (2022-2027)
8.2.3.5. Southeast Asia Oral Anti-Diabetic Market Forecast (2022-2027)
8.2.3.6. Rest of Asia-Pacific Oral Anti-Diabetic Market Forecast (2022-2027)
8.2.4. South America Oral Anti-Diabetic Market Forecast (2022-2027)
8.2.4.1. Brazil Oral Anti-Diabetic Market Forecast (2022-2027)
8.2.4.2. Argentina Oral Anti-Diabetic Market Forecast (2022-2027)
8.2.4.3. Columbia Oral Anti-Diabetic Market Forecast (2022-2027)
8.2.4.4. Rest of South America Oral Anti-Diabetic Market Forecast (2022-2027)
8.2.5. Middle East and Africa Oral Anti-Diabetic Market Forecast (2022-2027)
8.2.5.1. Saudi Arabia Oral Anti-Diabetic Market Forecast (2022-2027)
8.2.5.2. United Arab Emirates Oral Anti-Diabetic Market Forecast (2022-2027)
8.2.5.3. Egypt Oral Anti-Diabetic Market Forecast (2022-2027)
8.2.5.4. Nigeria Oral Anti-Diabetic Market Forecast (2022-2027)
8.2.5.5. South Africa Oral Anti-Diabetic Market Forecast (2022-2027)
8.2.5.6. Turkey Oral Anti-Diabetic Market Forecast (2022-2027)
8.2.5.7. Rest of Middle East and Africa Oral Anti-Diabetic Market Forecast (2022-2027)
8.3. Oral Anti-Diabetic Market Forecast by Type (2022-2027)
8.3.1. Oral Anti-Diabetic Forecast by Type (2022-2027)
8.3.2. Oral Anti-Diabetic Market Share Forecast by Type (2022-2027)
List of Tables
List of Tables and Figures:
Figure United States Oral Anti-Diabetic Revenue (Million USD) and Growth Rate (2017-2027)
Figure Canada Oral Anti-Diabetic Revenue (Million USD) and Growth Rate (2017-2027)
Figure Mexico Oral Anti-Diabetic Revenue (Million USD) and Growth Rate (2017-2027)
Figure Germany Oral Anti-Diabetic Revenue (Million USD) and Growth Rate (2017-2027)
Figure France Oral Anti-Diabetic Revenue (Million USD) and Growth Rate (2017-2027)
Figure UK Oral Anti-Diabetic Revenue (Million USD) and Growth Rate (2017-2027)
Figure Russia Oral Anti-Diabetic Revenue (Million USD) and Growth Rate (2017-2027)
Figure Italy Oral Anti-Diabetic Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of Europe Oral Anti-Diabetic Revenue (Million USD) and Growth Rate (2017-2027)
Figure China Oral Anti-Diabetic Revenue (Million USD) and Growth Rate (2017-2027)
Figure Japan Oral Anti-Diabetic Revenue (Million USD) and Growth Rate (2017-2027)
Figure Korea Oral Anti-Diabetic Revenue (Million USD) and Growth Rate (2017-2027)
Figure India Oral Anti-Diabetic Revenue (Million USD) and Growth Rate (2017-2027)
Figure Southeast Asia Oral Anti-Diabetic Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of Asia-Pacific Oral Anti-Diabetic Revenue (Million USD) and Growth Rate (2017-2027)
Figure Brazil Oral Anti-Diabetic Revenue (Million USD) and Growth Rate (2017-2027)
Figure Argentina Oral Anti-Diabetic Revenue (Million USD) and Growth Rate (2017-2027)
Figure Columbia Oral Anti-Diabetic Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of South America Oral Anti-Diabetic Revenue (Million USD) and Growth Rate (2017-2027)
Figure Saudi Arabia Oral Anti-Diabetic Revenue (Million USD) and Growth Rate (2017-2027)
Figure United Arab Emirates Oral Anti-Diabetic Revenue (Million USD) and Growth Rate (2017-2027)
Figure Egypt Oral Anti-Diabetic Revenue (Million USD) and Growth Rate (2017-2027)
Figure Nigeria Oral Anti-Diabetic Revenue (Million USD) and Growth Rate (2017-2027)
Figure South Africa Oral Anti-Diabetic Revenue (Million USD) and Growth Rate (2017-2027)
Figure Turkey Oral Anti-Diabetic Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of Middle East and Africa Oral Anti-Diabetic Revenue (Million USD) and Growth Rate (2017-2027)
Table Global Oral Anti-Diabetic Revenue and Revenue Share by Type (2017-2019)
Figure Global Sulfonylureas Revenue and Growth Rate (2017-2019)
Figure Global Biguanides Revenue and Growth Rate (2017-2019)
Figure Global Alpha-Glucosidase Inhibitors Revenue and Growth Rate (2017-2019)
Figure Global Megalitinides Revenue and Growth Rate (2017-2019)
Figure Global Others Revenue and Growth Rate (2017-2019)
Table Global Oral Anti-Diabetic Revenue by Regions (2017-2019)
Figure North America Oral Anti-Diabetic Growth Rate (2017-2019)
Figure North America Oral Anti-Diabetic Revenue and Growth Rate (2017-2019)
Figure North America Oral Anti-Diabetic by Countries (2017-2019)
Figure North America Oral Anti-Diabetic Revenue (Million USD) by Countries (2017-2019)
Figure United States Oral Anti-Diabetic Growth Rate (2017-2019)
Figure United States Oral Anti-Diabetic Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Canada Oral Anti-Diabetic Growth Rate (2017-2019)
Figure Canada Oral Anti-Diabetic Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Mexico Oral Anti-Diabetic Growth Rate (2017-2019)
Figure Mexico Oral Anti-Diabetic Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Europe Oral Anti-Diabetic Growth Rate (2017-2019)
Figure Europe Oral Anti-Diabetic Revenue and Growth Rate (2017-2019)
Figure Europe Oral Anti-Diabetic by Countries (2017-2019)
Figure Europe Oral Anti-Diabetic Revenue (Million USD) by Countries (2017-2019)
Figure Germany Oral Anti-Diabetic Growth Rate (2017-2019)
Figure Germany Oral Anti-Diabetic Revenue (Millions USD) and Growth Rate (2017-2019)
Figure France Oral Anti-Diabetic Growth Rate (2017-2019)
Figure France Oral Anti-Diabetic Revenue (Millions USD) and Growth Rate (2017-2019)
Figure UK Oral Anti-Diabetic Growth Rate (2017-2019)
Figure UK Oral Anti-Diabetic Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Russia Oral Anti-Diabetic Growth Rate (2017-2019)
Figure Russia Oral Anti-Diabetic Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Italy Oral Anti-Diabetic Growth Rate (2017-2019)
Figure Italy Oral Anti-Diabetic Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Rest of Europe Oral Anti-Diabetic Growth Rate (2017-2019)
Figure Rest of Europe Oral Anti-Diabetic Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Asia-Pacific Oral Anti-Diabetic Growth Rate (2017-2019)
Figure Asia-Pacific Oral Anti-Diabetic Revenue and Growth Rate (2017-2019)
Figure Asia-Pacific Oral Anti-Diabetic by Countries (2017-2019)
Figure Asia-Pacific Oral Anti-Diabetic Revenue (Million USD) by Countries (2017-2019)
Figure China Oral Anti-Diabetic Growth Rate (2017-2019)
Figure China Oral Anti-Diabetic Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Japan Oral Anti-Diabetic Growth Rate (2017-2019)
Figure Japan Oral Anti-Diabetic Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Korea Oral Anti-Diabetic Growth Rate (2017-2019)
Figure Korea Oral Anti-Diabetic Revenue (Millions USD) and Growth Rate (2017-2019)
Figure India Oral Anti-Diabetic Growth Rate (2017-2019)
Figure India Oral Anti-Diabetic Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Southeast Asia Oral Anti-Diabetic Growth Rate (2017-2019)
Figure Southeast Asia Oral Anti-Diabetic Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Rest of Asia-Pacific Oral Anti-Diabetic Growth Rate (2017-2019)
Figure Rest of Asia-Pacific Oral Anti-Diabetic Revenue (Millions USD) and Growth Rate (2017-2019)
Figure South America Oral Anti-Diabetic Growth Rate (2017-2019)
Figure South America Oral Anti-Diabetic Revenue and Growth Rate (2017-2019)
Figure South America Oral Anti-Diabetic by Countries (2017-2019)
Figure South America Oral Anti-Diabetic Revenue (Million USD) by Countries (2017-2019)
Figure Brazil Oral Anti-Diabetic Growth Rate (2017-2019)
Figure Brazil Oral Anti-Diabetic Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Argentina Oral Anti-Diabetic Growth Rate (2017-2019)
Figure Argentina Oral Anti-Diabetic Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Columbia Oral Anti-Diabetic Growth Rate (2017-2019)
Figure Columbia Oral Anti-Diabetic Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Rest of South America Oral Anti-Diabetic Growth Rate (2017-2019)
Figure Rest of South America Oral Anti-Diabetic Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Middle East and Africa Oral Anti-Diabetic Growth Rate (2017-2019)
Figure Middle East and Africa Oral Anti-Diabetic Revenue and Growth Rate (2017-2019)
Figure Middle East and Africa Oral Anti-Diabetic by Countries (2017-2019)
Figure Middle East and Africa Oral Anti-Diabetic Revenue (Million USD) by Countries (2017-2019)
Figure Saudi Arabia Oral Anti-Diabetic Growth Rate (2017-2019)
Figure Saudi Arabia Oral Anti-Diabetic Revenue (Millions USD) and Growth Rate (2017-2019)
Figure United Arab Emirates Oral Anti-Diabetic Growth Rate (2017-2019)
Figure United Arab Emirates Oral Anti-Diabetic Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Egypt Oral Anti-Diabetic Growth Rate (2017-2019)
Figure Egypt Oral Anti-Diabetic Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Nigeria Oral Anti-Diabetic Growth Rate (2017-2019)
Figure Nigeria Oral Anti-Diabetic Revenue (Millions USD) and Growth Rate (2017-2019)
Figure South Africa Oral Anti-Diabetic Growth Rate (2017-2019)
Figure South Africa Oral Anti-Diabetic Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Turkey Oral Anti-Diabetic Growth Rate (2017-2019)
Figure Turkey Oral Anti-Diabetic Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Rest of Middle East and Africa Oral Anti-Diabetic Growth Rate (2017-2019)
Figure Rest of Middle East and Africa Oral Anti-Diabetic Revenue (Millions USD) and Growth Rate (2017-2019)
Table Abbott Oral Anti-Diabetic Financial Overview
Table AstraZeneca Oral Anti-Diabetic Financial Overview
Table Biocon Oral Anti-Diabetic Financial Overview
Table Eli Lilly and Company Oral Anti-Diabetic Financial Overview
Table Merck & Co., Inc. Oral Anti-Diabetic Financial Overview
Table Novartis AG Oral Anti-Diabetic Financial Overview
Table Novo Nordisk A/S Oral Anti-Diabetic Financial Overview
Table Pfizer Inc. Oral Anti-Diabetic Financial Overview
Table Sanofi Oral Anti-Diabetic Financial Overview
Table Sun Pharmaceutical Industries Ltd Oral Anti-Diabetic Financial Overview
Figure Global Oral Anti-Diabetic Revenue (Millions USD) and Growth Rate (2019-2027)
Table Oral Anti-Diabetic Market Forecast by Regions (2019-2027)
Figure North America Oral Anti-Diabetic Market Forecast (2019-2027)
Figure United States Oral Anti-Diabetic Market Forecast (2019-2027)
Figure Canada Oral Anti-Diabetic Market Forecast (2019-2027)
Figure Mexico Oral Anti-Diabetic Market Forecast (2019-2027)
Figure Europe Oral Anti-Diabetic Market Forecast (2019-2027)
Figure Germany Oral Anti-Diabetic Market Forecast (2019-2027)
Figure France Oral Anti-Diabetic Market Forecast (2019-2027)
Figure UK Oral Anti-Diabetic Market Forecast (2019-2027)
Figure Russia Oral Anti-Diabetic Market Forecast (2019-2027)
Figure Italy Oral Anti-Diabetic Market Forecast (2019-2027)
Figure Rest of Europe Oral Anti-Diabetic Market Forecast (2019-2027)
Figure Asia-Pacific Oral Anti-Diabetic Market Forecast (2019-2027)
Figure China Oral Anti-Diabetic Market Forecast (2019-2027)
Figure Japan Oral Anti-Diabetic Market Forecast (2019-2027)
Figure Korea Oral Anti-Diabetic Market Forecast (2019-2027)
Figure India Oral Anti-Diabetic Market Forecast (2019-2027)
Figure Southeast Asia Oral Anti-Diabetic Market Forecast (2019-2027)
Figure Rest of Asia-Pacific Oral Anti-Diabetic Market Forecast (2019-2027)
Figure South America Oral Anti-Diabetic Market Forecast (2019-2027)
Figure Brazil Oral Anti-Diabetic Market Forecast (2019-2027)
Figure Argentina Oral Anti-Diabetic Market Forecast (2019-2027)
Figure Columbia Oral Anti-Diabetic Market Forecast (2019-2027)
Figure Rest of South America Oral Anti-Diabetic Market Forecast (2019-2027)
Figure Middle East and Africa Oral Anti-Diabetic Market Forecast (2019-2027)
Figure Saudi Arabia Oral Anti-Diabetic Market Forecast (2019-2027)
Figure United Arab Emirates Oral Anti-Diabetic Market Forecast (2019-2027)
Figure Egypt Oral Anti-Diabetic Market Forecast (2019-2027)
Figure Nigeria Oral Anti-Diabetic Market Forecast (2019-2027)
Figure South Africa Oral Anti-Diabetic Market Forecast (2019-2027)
Figure Turkey Oral Anti-Diabetic Market Forecast (2019-2027)
Figure Rest of Middle East and Africa Oral Anti-Diabetic Market Forecast (2019-2027)
Figure Global Oral Anti-Diabetic Forecast by Type (2019-2027)
Figure Global Oral Anti-Diabetic Market Share Forecast by Type (2019-2027)
Figure Global Oral Anti-Diabetic Forecast by Type (2019-2027)
Please Note: Data related to the Companies are subject to Availability.
Research Methodology
We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.
Data Mining
Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.
Data Collection Matrix
|
Data Collection Matrix |
Supply Side |
Demand Side |
|
Primary Data Sources |
|
|
|
Secondary Data Sources |
|
|
Market Modeling and Forecasting
We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.
- Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
- Number of patients for particular device or medical procedure and
- Repeated use of particular device depending on health and condition of patient
- Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.
We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.
Data Validation
We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.
Data Triangulation
Industry Analysis
|
Qualitative Data |
Quantitative Data (2017-2025) |
|
|